Amunix secures $117M to move lead candidate to clinical trials

By The Science Advisory Board staff writers

March 4, 2021 -- Amunix Pharmaceuticals has raised $117 million in financing to fund the advancement of its lead T-cell engager candidate into the clinic.

AMX-818, the company's lead candidate, is a masked, protease-activated T-cell engager (XPAT) targeting human epidermal growth factor receptor 2 (HER2)-expressing solid tumors that are preferentially activated in the tumor microenvironment.

The funds will also support Amunix's pipeline of earlier stage XPATs and other masked, protease-activated cytokines (XPACs). The candidates were developed using the company's unstructured polypeptide XTEN polymer technology and have been validated in human cells.

The funding round was led by Viking Global Investors.

Janux, Merck partner on T-cell engager immunotherapies
Janux Therapeutics has entered into a strategic collaboration and licensing agreement with Merck to discover, develop, and commercialize next-generation...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter